Intellipharmaceutics International Inc. With a strong emphasis on technological innovation, Intellipharmaceutics has established itself as a pioneer in controlled-release and targeted-release drug delivery systems. Founded by Drs.

Isa and Amina Odidi in 1998, the company has a rich history of developing and commercializing FDA-approved controlled release drugs. Today, Intellipharmaceutics boasts a diverse portfolio of seven proprietary drug delivery technologies and over 100 patents, setting the stage for the development of both generic and novel product candidates. Operating from a state-of-the-art facility in Toronto, Canada, Intellipharmaceutics adheres to strict quality control standards and holds FDA and Health Canada certifications.

Their dedicated team of professionals covers the entire research and development process, from formulation development to manufacturing and regulatory affairs. With a strategic focus on controlled-release generic drugs, Intellipharmaceutics provides solutions for challenging medical conditions. By harnessing their expertise in controlled-release drug delivery, they aim to deliver medications that provide sustained therapeutic effects, improving patient outcomes and quality of life.

Intellipharmaceutics' commitment to innovation and excellence makes them a trusted partner for drug development, analytical services, and abuse deterrent studies. Partner with them to explore the future of pharmaceuticals